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818-5 Percutaneous Transfemoral Coronary and Peripheral 
Procedures via Aortofemoral Synthetic Vascular Grafts: 
A Review of 123 Diagnostic and Interventional Cases
Michael J. Gallagher, Simon R. Dixon, Mohan C. Madala, Renny Abraham, Steven D. 
Rimar, William W. O'Neill, Joel K. Kahn, William Beaumont Hospital, Royal Oak, MI
Background: Few data exist regarding the incidence of vascular complications associ-
ated with transfemoral catheterization and sheath placement into synthetic vascular
grafts.
Methods: We performed a retrospective analysis of all patients who underwent
aortofemoral bypass surgery at our institution between January, 1991 and July, 2003.
Those patients who underwent subsequent transfemoral catheterization were selected. A
total of 123 procedures were performed in 70 patients between February, 1994 and April,
2003.
Results: One hundred and thirteen coronary (91.9%) and 10 peripheral (8.1%) proce-
dures were performed, including sixty-four (52.0%) interventional (angioplasty and/or
stent), and 59 (48%) diagnostic procedures. Two of the interventional procedures
included placement of an intraaortic balloon pump via the graft. The interval between
graft implantation and sheath placement was 2.9 + 2.1 years (range 4 days to 10.3
years). Four procedures (3.3%) required concomitant brachial or radial access due to
inability to access the ascending aorta via the femoral approach. Pre-procedural antico-
agulation included aspirin (91.9%), clopidogrel (28.5%), warfarin (10.6%), and intrave-
nous heparin (39.0%). The peak activated clotting time was 313 + 89 seconds. The
procedure time was 53.2 + 34.1 minutes, and sheaths were pulled an average of 5.2
hours after catheterization. Adverse events related to vascular access occurred in 8/123
(6.5%) procedures. Complications included blood transfusion (4.1%), thrombotic occlu-
sion (1.6%), and retroperitoneal bleed (0.8%). The two cases of thrombotic occlusion
were associated with early clinical signs of diminished perfusion. One patient required
surgical thrombectomy and the other was treated with intraarterial local thrombolysis.
There were no cases of graft infection or pseudoaneurysm formation, nor any deaths
attributable to vascular access complications.
Conclusion: Transfemoral sheath entry into a synthetic aortofemoral bypass graft is
associated with a low incidence of adverse vascular events. However, careful observation
and follow up during the 24-hour post catheterization period is critical.
3:15 p.m.
818-6 Women Remain at Higher Risk for Retroperitoneal 
Hematoma After Percutaneous Coronary Intervention in 
the Era of Glycoprotein IIb/IIIa Inhibitors and Vascular 
Closure Devices
H M Omar Farouque, Jennifer A. Tremmel, Meenakshi Aggarwal, Farshad Raissi 
Shabari, William F. Fearon, Mehrdad Rezaee, Alan C. Yeung, David P. Lee, Stanford 
University Medical Center, Stanford, CA
Background: The incidence, clinical features, and determinants of retroperitoneal
hematoma (RPH) after percutaneous coronary intervention (PCI) have been previously
described. We examined these variables in the current era of widespread glycoprotein
(GP) IIb/IIIa inhibitors and vascular closure devices (VCDs).
Methods: 3,230 PCI procedures were performed from January 2000 to August 2003.
There were 22 cases of radiographically documented RPH. Cases were compared to a
random sample of 50 controls using chi-square and logistic regression.
Results: The incidence of RPH was 6.8/1000 cases. Mean age±SD was 67±12 years in
both groups. Cases and controls did not differ in prevalence of hypertension, diabetes, or
hyperlipidemia. Median time from procedure end to onset of clinical signs was 126 min-
utes (range 15-840). Symptoms included lower abdominal pain (59%), diaphoresis
(59%), groin pain (45%), and back pain (18%). Groin hematoma was evident in 32%.
Hypotension occurred in 91%, with a mean BP nadir of 78/40 mmHg. Bradycardia requir-
ing atropine occurred in 36%. Hematocrit dropped from 37.5±3.4% to 27.1±3.8%
(p=0.007). All cases had blood loss anemia and at least two of the above clinical fea-
tures. Mean hospital stay was longer in RPH cases (2.2±1.3 vs. 1.7±1.5 days, p=0.06).
The use of GP IIb/IIIa inhibitors and the method of vascular closure had no effect on the
risk of RPH. There was also no association between RPH and acuity of PCI (elective vs.
emergent), duration of procedure, heparin dose, ACT level, arterial sheath size, insertion
of a venous sheath, or prior femoral artery puncture. Female sex was most strongly asso-
ciated with RPH (OR 5.0, 95% CI 1.7-14.5). Angiographic analysis revealed that a higher
femoral artery puncture in relation to the femoral head (superior third of the femoral head
and higher vs. mid third and lower) was also associated with RPH (OR 4.2, 95% CI 1.3-
14.0).
Conclusion: With the widespread use of GP IIb/IIIa inhibitors and VCDs, being a woman
remains a significant risk factor for RPH, as does a more superior femoral artery punc-
ture. Awareness of the determinants and clinical features of RPH may aid in prevention,
early recognition, and prompt treatment.
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1100-55 Intravenous Mesenchymal Stem Cell Therapy Early 
After Reperfused Acute Myocardial Infarction Improves 
Left Ventricular Function and Alters Ventricular 
Electrophysiologic Properties
Matthew J. Price, Chung-Chuan Chou, Malka Frantzen, Takashi Miyamoto, Saibal Kar, 
Dougal McClean, Suzhen Guo, Steve Lee, Prediman K. Shah, Bradley J. Martin, Michael 
Lill, James S. Forrester, Peng-Sheng Chen, Raj R. Makkar, Cedars Sinai Medical Center, 
Los Angeles, CA
Background: Direct intramyocardial injection of stem cells improves LV function. How-
ever, the injection of immature cells has been associated with an increased risk of ven-
tricular arrhythmia. We hypothesized that the IV infusion of allogeneic mesenchymal
stem cells (MSCs) without immunosuppresion after acute MI would improve LV function
but might be accompanied by pro-arrhythmic electrical remodeling.
Methods: An apical MI was induced in swine by balloon occlusion-reperfusion of the
mid-LAD. Animals received either no treatment, or, 30 minutes after reperfusion, DiI-
labeled allogeneic bone marrow derived MSCs (3.2±0.4 x 108 cells) were infused IV. LV
function was evaluated by LV cineangiography and wall thickness by echocardiography.
Epicardial effective refractory periods (ERPs) were determined at 3 month sacrifice.
Spectral imaging by confocal microscopy was used to identify Di-I in tissue specimens.
Results: At 3 months, MSC treated pigs [n=7] had significantly higher LVEF than con-
trols [n=8] (50±1% vs 44±1%, p=0.015), as well as significantly higher LV systolic pres-
sure (144±5 mmHg vs. 119±5 mmHg, p=0.01). The mean increase in LVEDV over time
tended to be greater in the control group (48+6cm3 vs.32+6cm3, p=0.09). The wall thick-
ness of normal, non-infarcted myocardium increased significantly more in controls than in
treated animals. ERPs of the MSC group were significantly shorter than controls at all
pacing cycle lengths in LV peri-infarct, LV free wall (FW), and right ventricular (RV) FW
(225+6, 227+5, 225+6 ms, vs 251+6, 251+6, 247+7 ms, all p<=0.002). The mean slope
of the ERP restitution curves was steeper in the MSC group than in controls (1.6±0.8 vs
1.0±0.4, p=0.02). DiI was identified in the lungs and myocardium of treated animals.
Conclusions: IV infusion of MSCs soon after reperfused acute MI in swine improves LV
function, lessens compensatory hypertrophy of non-infarcted myocardium, shortens ERP,
and steepens the ERP restitution curve. Clinical trials assessing the efficacy of IV MSC
therapy after MI in humans should include arrhythmia monitoring.
1100-56 Comparison Between Intracoronary Infusion and Direct 
Transendocardial Injection of Mesenchymal Stem Cells 
in a Dog Acute Ischemia Model
Emerson C. Perin, Joao A. Assad, Guilherme V. Silva, Stephanie Coulter, Judy Ober, 
Jing Lin, Andre L. Sousa, Silvio Litowski, Yong Geng, Bradley J. Martin, William K. 
Vaughn, James T. Willerson, Texas Heart Institute, Houston, TX
Background: Experimental data suggest that mesencymal stem cell (MSC) therapy con-
tributes to healing after acute myocardial infarction(AMI). The ideal route of administra-
tion is still contrversial.
Methods: A total of 10 dogs were divided in three groups:a)Control n=3; b)Intracoronary
(IC) n=3 and c) NOGA guided transendocardial injections (TEI) n=4. All animals had an
anterior wall AMI induced by ligation of LAD artery for three hours and then reperfused.
The animals received cell therapy (100 million MSC's(Osiris)) 1 wk after AMI and were
sacrificed 2 wks after cell therapy. 2D-echo was performed immediately before AMI, cell
therapy and sacrifice. NOGA mapping was performed immediately before cell therapy
and sacrifice. Ischemic area was measured by NOGA. ANOVA was performed.
Results: The 2D-echo findings concerning ejection fraction (EF), end-diastolic dimension
(EDD), end-systolic dimension (ESD), and ischemic area are presented in table 1. The
TEI group had a statistically significant increase in EF (p=0.006), a reduction in
EDD(p=0.04), a reduction in ESD (p=0.02), and more importantly a reduction in ischemic
area (p=0.006) when compared to the control group. All the other comparisons did not
reach statistical significance (p>0.05).
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Conclusion: There were no complications associated with TEI after AMI. This preliminary
data with a small number of animals suggests that NOGA guided TEI may be superior to
IC delivery. Thus, direct delivery of MSC's may play an important role even after an AMI .
1100-57 Catheter-Based Transplantation of Autologous Bone 
Marrow Mononuclear Cells Safely Improves Collateral 
and Capillary Network in Adult Swine With Myocardial 
Ischemia
Aysegul Yegin, Mio Ebato, Fernando Tondato, Bunken Ebato, Jianhua Cui, Traci 
Goodchild, Stephen C. Frohwein, Jesse Rios, James F. Sanzo, Keith Robinson, Mark 
Ungs, Nicolas A. Chronos, American Cardiovascular Research Institute, Atlanta, GA
Background: To date, it is unclear whether intramyocardial transplantation of autologous
bone marrow derived mononuclear cells (BM-MNCs) enhances neovascularization in
adult myocardium. We tested the hypothesis that catheter-based delivery of BM-MNCs
augments neovascularization in an adult porcine model of chronic ischemia. Methods:
Ameroid constrictor was implanted around proximal left circumflex coronary artery (LCX)
in adult Yucatan swine. Animals with LCX occlusion of < 90% were excluded from the
study. At 4 weeks, pigs were randomized to receive freshly isolated BM-MNCs (n=8) or
culture medium (DMEM) as control (n=8). Under general anesthesia, bone marrow (30-
50 ml) was aspirated from sternum and if necessary, iliac crest. Mononuclear cells were
isolated using density-gradient centrifugation method (Histopaque 1077). A total of 1 x
108 cells were injected at 10 sites (5 in the ischemic, and 5 in the non-ischemic region)
using Boston Scientific StilettoTM catheter with intracardiac echocardiography (ICE) guid-
ance. Baseline (4 wk) and follow-up (8 wk) evaluations included coronary angiography
(Rentrop score), dobutamine stress echocardiography, and myocardial blood flow by
microspheres. Tracking of BM-MNCs was performed in additional pigs (n=3). Tissue
samples were stained with PKH-26 to verify cell viability and DAPI (diamino-phenylin-
dole) for intact nuclear DNA, 2 and 4 weeks after delivery. Results: Collateral (Rentrop)
Scores: Left-to-left collaterals significantly improved in the BM-MNC treated group
(p=0.031). Cell tracking study: Ischemic areas contained higher amount of PKH-26 posi-
tive cells co-localizing with DAPI, compared to non-ischemic regions. Transplanted BM-
MNCs clustered in areas without abundant cellular structure. A significant increase was
found in total capillary area in the LCX (ischemic) region in endocardial (p=0.016) and
epicardial (p=0.044) sections in BM-MNC treated pigs compared to the control group.
Conclusion: Catheter-based intramyocardial transplantation of autologous BM-MNCs
safely enhances collateral and capillary network in adult swine with chronic myocardial
ischemia.
1100-58 Interpretation of the Actual Platelet Inhibition Induced 
by Clopidogrel: A New Look at How to Represent Drug 
Response
Paul A. Gurbel, Waiel M. Samara, Kevin P. Bliden, Sinai Center for Thrombosis 
Research, Baltimore, MD
Background: Mean pre- and post- treatment % platelet aggregation is commonly used
to describe clopidogrel- induced inhibition and may miss non-responders. Methods: Indi-
vidual responses to clopidogrel were studied by 5 µM ADP aggregation (A) in pts ( n = 68
) pre and at 5 days post-stenting. All pts received aspirin 325mg ; 300 mg clopidogrel at
the time of stenting ; and 75mg qd . A was recorded as the maximum % change in light
transmittance from baseline. Individual responses were measured at 5 days as the abso-
lute change in aggregation (∆ A) from pre-to post-treatment. (∆ A= pre-treatment A minus
post-treatment A ; non-response = ∆ A <10%.
Results: Pre-treatment A was 60 ± 17 and fell to 35 ± 17 after clopidogrel (p<.0001, 42%
relative inhibition ) and 16/68 patients (24%) were non-responders ( figure ). Non-
responders had higher platelet reactivity (p=.0002). However, total group A was not sig-
nificantly different from the group of responders ( p = .34 ). By reporting the data as ∆A
the presence of non- responders in unmasked (figure).
Conclusion: Non-responders are entirely unrecognized by the current practice of report-
ing mean aggregation data that overestimates the actual drug effect in certain patients.
Clinicians should be aware of non-response and its potential effect on outcomes. We rec-
ommend a more accurate approach to estimate the drug’s effect would be to account for
those patients who are non-responsive by reporting the individual change in aggregation
from pre-treatment to post-treatment. 
1100-59 High-Dose Clopidogrel Loading Rapidly Reduces Both 
Platelet Inflammatory Marker Expression and 
Aggregation
Frank J. Zidar, David J. Moliterno, Deepak L. Bhatt, Kandice Kottke-Marchant, Marelene 
Goormastic, Edward F. Plow, Eric J. Topol, Cleveland Clinic, Cleveland, OH
Background: Pretreatment with the platelet antagonist clopidogrel has been shown to
reduce short and long-term ischemic events after percutaneous coronary intervention.
The optimal clopidogrel loading dose and the timing of its benefit remain unclear. More-
over, it is uncertain whether these benefits are from inhibition of platelet-mediated aggre-
gation, inflammation, or both. We sought to determine the response to a 300mg
clopidogrel loading versus a 600mg (high dose) loading on the time-course of aggrega-
tion and inflammation suppression.
Methods: 12 healthy volunteers were given 300mg of clopidogrel, and blood samples
were obtained at baseline and 2, 4, and 6 hours. After a 2-week washout period, these
subjects were given 600mg of clopidogrel and serial blood sampling was repeated. Plate-
let aggregation was quantified using turbidimetric aggregometry with ADP (20uM) as the
agonist, and results were evaluated as percent inhibition of baseline aggregation. Platelet
CD40L and P-selectin expression in ADP-activated samples were quantified by flow
cytometry, and results were evaluated as percent positive cells. 
Results: Complete data were available on 10 subjects, 50% men with a mean of 35
years (+/- 7 SD). 
Conclusion: Beyond a greater early inhibition of platelet aggregation, a high loading 
dose of clopidogrel rapidly and more effectively suppresses platelet inflammatory mark-
ers. These anti-inflammatory effects likely play a key role in the clinical benefit from clopi-
dogrel pretreatment.
Control TEI IC
pre-cells post-cells pre-cells post-cells pre-cells post-cells
EDD(mm) 4.2±0.1 3.97±0.19 3.9±0.3 3.55±0.15 4.0±0.08 3.93±0.26
ESD(mm) 3.47±0.04 3.17±0.2 3.1±0.3 2.65±0.33 3.1±0.25 3±0.21
EF(%) 32±1.41 34±2.9 33±3.2 49±9 34±2.1 41±4.3
Ischemic 
Area(%LV)
19.8±4 20.4±8 37.9±9.8 6.8±5.3 25.8±11.7 6±4.3
Dose
(mg)
Time (hours) : Mean
0 2 4 6
% Inhibition
from baseline
aggregation
300 0 34.6 32.7 33.5
600 0 48.2* 43.9* 50.9*
Difference between 300 and 600 at 0 (p=NS), 2 (p=0.009), 4 (p=0.02), 6 (p=0.0008)
CD40L
% positive
cells
300 27.0 21.4 13.7 18.6
600 24.0 16.0 11.6 9.8*
Difference between 300 and 600 at 0, 2 and 4 hours (p=NS); 6 hours (p=0.01)
P-selectin
% positive
cells
300 88.6 84.1 82.4 81.9
600 81.1 75.7 72.3* 67.1*
Difference between 300 and 600 at 0 and 2 (p=NS), 4 hours (p=0.02), 6 hours (p=0.05)
